HOLDER OF MDA LICENSES : AUTHORISED REPRESENTATIVE / IMPORTER / DISTRIBUTOR & GDPMD

TOOP Capital
  • Home
  • About Us
  • Our Services
  • Market Entry Reports
  • 7 Step Process
  • Insights
  • Contact Us
  • Access Strategies
    • Snap Shot
    • Blue Print
    • Deep Dive
  • More
    • Home
    • About Us
    • Our Services
    • Market Entry Reports
    • 7 Step Process
    • Insights
    • Contact Us
    • Access Strategies
      • Snap Shot
      • Blue Print
      • Deep Dive
TOOP Capital
  • Home
  • About Us
  • Our Services
  • Market Entry Reports
  • 7 Step Process
  • Insights
  • Contact Us
  • Access Strategies
    • Snap Shot
    • Blue Print
    • Deep Dive

deep dive

PRICE AT - US$1750+

The Malaysia Market Entry Deep Dive is our most comprehensive market-entry report, designed for medical device manufacturers that are seriously evaluating, budgeting for or preparing to enter Malaysia.

This is where market research becomes an execution strategy.

Rather than looking at regulation, competition, pricing, distribution and procurement independently, the Deep Dive brings them together to answer one critical question:


HOW DO WE TURN THIS PRODUCT INTO A VIABLE MALAYSIAN MARKET-ENTRY BUSINESS?


Every Deep Dive is built specifically around the manufacturer, product, regulatory position, target customers, competitive environment and commercial objectives.


WHAT YOUR DEEP DIVE COVERS

PRODUCT & MANUFACTURER ASSESSMENT


Detailed assessment of the device, intended use, technology, existing regulatory position, international approvals, commercial objectives and proposed Malaysian strategy.


DETAILED MARKET OPPORTUNITY


Product-specific analysis of the Malaysian opportunity, including relevant market drivers, demand, customer groups and addressable market.

Where reliable data is available, analysis may incorporate relevant procedure, patient, testing, installation or utilisation volumes.


CUSTOMER & MARKET MAPPING


Identification and prioritisation of relevant potential customers depending on the technology, including:

Hospitals • Laboratories • Clinics • Specialists • Pharmacies • Healthcare Groups • Distributors • Government / Private Procurement

The objective is not simply to identify who could buy the product, but where the strongest opportunities may exist.


COMPETITOR INTELLIGENCE


Detailed assessment of relevant competitors, products and alternative technologies.

We consider:

Market positioning • product differentiation • incumbent technologies • pricing • customer relationships • switching barriers • potential competitive advantages


PRICING & COMMERCIAL ECONOMICS


Assessment of the likely Malaysian pricing environment and how pricing interacts with the commercial structure.

This may include:

Indicative market pricing • competitive pricing • manufacturer pricing • channel margins • landed economics • distributor economics • final customer positioning

The objective is to establish whether the opportunity can make sense commercially as well as clinically.


DETAILED REGULATORY PATHWAY


A deeper assessment of the anticipated Malaysian regulatory pathway, including:

  • Indicative device classification 
  • Applicable regulatory pathway 
  • Existing approval/evidence considerations 
  • Conformity assessment considerations 
  • CAB pathway where applicable 
  • Registration requirements 
  • Authorised Representative requirements 
  • Indicative regulatory sequencing 
  • Indicative timelines 
  • Key regulatory risks 


TECHNICAL DOCUMENTATION & GAP ASSESSMENT


Assessment of the principal documentation likely to be required for Malaysian registration, including relevant elements of the technical dossier/CSDT.

Potential gaps, weaknesses or additional information requirements are identified before significant regulatory work begins.


MARKET-ENTRY STRUCTURE


We consider how the manufacturer could structure the Malaysian pathway across:


AUTHORISED REPRESENTATION

↓

REGISTRATION

↓

IMPORTATION

↓

DISTRIBUTION

↓

COMMERCIALISATION

↓

POST-MARKET RESPONSIBILITIES


The objective is to ensure the regulatory structure supports the intended commercial model.


DISTRIBUTION & CHANNEL STRATEGY


Detailed assessment of the channels most appropriate for the specific technology.

This can include:

  • Distributor requirements 
  • Ideal partner profile 
  • Channel structure 
  • Direct versus distributor-led considerations 
  • Specialist sales requirements 
  • Inventory considerations 
  • Clinical/application support 
  • Training requirements 
  • Potential channel conflicts 
  • Partner evaluation criteria 

Rather than simply asking “Who can distribute?”, we ask:


“WHAT TYPE OF COMMERCIAL PARTNER COULD ACTUALLY BUILD THIS PRODUCT?”


PROCUREMENT & MARKET ACCESS


Assessment of how relevant Malaysian customers may purchase the technology.

Depending on the product, this may include consideration of:

Private hospital procurement • Government opportunities • Healthcare groups • Laboratories • Pharmacy channels • Tenders • Direct purchasing • Distributor-led procurement

For specialist technologies, we also consider how clinical adoption and procurement may interact.


CLINICAL ADOPTION & COMMERCIALISATION


For technologies requiring behavioural or clinical change, registration alone may be insufficient.


The Deep Dive can consider:

KOL development • clinician education • demonstrations • training • evidence requirements • pilot opportunities • adoption barriers • value proposition

Because a registered product without adoption is still not a successful market entry.


RISK & SENSITIVITY ASSESSMENT


We challenge the business case.

What happens if:

Registration takes longer?

Pricing needs to fall?

Sales volumes are lower?

A distributor underperforms?

Competitors respond?

Procurement takes longer than expected?

The objective is to identify weaknesses before the manufacturer commits significant capital.


YOUR IMPLEMENTATION ROADMAP


The Deep Dive concludes with a prioritised roadmap covering:


  • WHAT TO DO
  • IN WHAT ORDER
  • WHY
  • WHAT IT MAY COST
  • HOW LONG IT MAY TAKE
  • WHERE THE PRINCIPAL RISKS ARE


This turns the report from market research into a practical decision and implementation tool.


EXECUTIVE STRATEGY SESSION INCLUDED


Following delivery, TOOP CAPITAL conducts an executive strategy session with the manufacturer to review the findings, challenge assumptions and discuss the recommended pathway.

This is an opportunity to move from:

“What does the report say?”

to:

“What are we going to do next?”


DELIVERABLE


40+ PAGE BESPOKE PDF REPORT

10–15 working day target delivery*
Executive strategy session included


FROM US$1,750


*Highly complex products, extensive product portfolios or projects requiring unusually detailed primary research may require additional time and quotation. Scope and delivery timeframe are agreed before commencement.


BEST FOR


The Deep Dive is designed for manufacturers asking:

“WE ARE SERIOUS ABOUT MALAYSIA. WHAT EXACTLY SHOULD WE DO?”


It is particularly suited to companies preparing to:

Allocate market-entry budget
Begin regulatory work
Appoint an Authorised Representative
Evaluate distributors
Establish pricing
Plan procurement
Develop commercialisation
Prepare for launch


How do we prepare to execute successfully?

WHY TOOP CAPITAL?


Our analysis is designed around the realities of taking a medical device from an overseas manufacturer into the Malaysian market.

TOOP CAPITAL's capabilities span Authorised Representation, Importation and Distribution, supported by GDPMD certification.

That allows us to look beyond whether a product can theoretically enter Malaysia and examine how the regulatory, supply-chain and commercial pieces need to work together.


REQUEST YOUR MARKET ENTRY DEEP DIVE REPORT BY GOOGLE FORM : https://forms.gle/fTPm6thRJDg3aUez5